Skip to content

Author

Pui-Yin Au-Yeung

We have 1 of 1 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.

Her2 TKIs may be the preferred initial option over ADCs in advanced HER2 mutated NSCLC, given their higher response rates, particularly in YVMA insertions, a more favorable safety profile, and preserved ADC efficacy following TKI exposure.

Molly S. C. Li, Yu Yang Soon, Pui-Yin Au-Yeung et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.